Regional differences in percutaneous coronary intervention outcomes in STEMI patients with diabetes: The Asia-Pacific evaluation of cardiovascular therapies (ASPECT) collaboration

Wong MYZ 1 , Yap JJL 2 , Chih HJ 3 , Yan BPY 4 , Fong AYY 5 , Beltrame JF 6 Show all authors , Wijaya IP 7 , Nguyen HTT 8 , Brennan AL 9 , Reid CM 10 , Yeo KK 11

Affiliations 

  • 1 Department of Cardiology, National Heart Centre Singapore, Singapore; School of Clinical Medicine, University of Cambridge, Cambridge, UK
  • 2 Department of Cardiology, National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore
  • 3 School of Population Health, Curtin University, Perth, Australia
  • 4 Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong
  • 5 Sarawak Heart Centre, Kota Samarahan, Malaysia
  • 6 Coronary Angiography Registry Database of South Australia (CARDOSA) registries, Australia
  • 7 Cardiology Division, Universitas Indonesia, Ciptomangunkusumo General Hospital, Indonesia
  • 8 Vietnam National Heart Institute, Bach Mai Hospital, Hanoi, Viet Nam
  • 9 Melbourne Interventional Group, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia
  • 10 School of Population Health, Curtin University, Perth, Australia; Melbourne Interventional Group, Melbourne, Australia; Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, Australia
  • 11 Department of Cardiology, National Heart Centre Singapore, Singapore; Duke-NUS Medical School, Singapore. Electronic address: yeo.khung.keong@singhealth.com.sg
Int J Cardiol, 2023 Jan 15;371:84-91.
PMID: 36220505 DOI: 10.1016/j.ijcard.2022.10.001

Abstract

BACKGROUND: Diabetes is associated with poorer outcomes and increased complication rates in STEMI patients undergoing percutaneous coronary intervention (PCI). Data are notably lacking in the Asia-Pacific region. We report the overall association of Diabetes with clinical characteristics and outcomes in STEMI patients undergoing PCI across the Asia-Pacific, with a particular focus on regional differences.

METHODOLOGY: The Asia Pacific Evaluation of Cardiovascular Therapies (ASPECT) collaboration consists of data from various PCI registries across Australia, Hong Kong, Singapore, Malaysia, Indonesia and Vietnam. Clinical characteristics, lesion characteristics, and outcomes were provided for STEMI patients. Key outcomes included 30-day overall mortality and major adverse cardiovascular events (MACE).

RESULTS: A total of 12,144 STEMI patients (mean(SD) age 59.3(12.3)) were included, of which 3912 (32.2%) had diabetes. Patients with diabetes were likely to have a higher baseline risk profile, poorer clinical presentation, and more complex lesion patterns (all p 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications